Skip to content
Jump to main navigation and login
Nav view search
You are here:
Latest Bing Center News
Dr. Edward Laane - Running for WM! (Part-2)
On November3, 2019, Dr. Edward Laane ran the Osaka Yodo River Half Marathon, to raise money for Waldenstrom's research. His pure running time was 2.26.07 with his official time listed at 2.31.0. As Dr. Laane recalls, "The run was difficult. It was sunny, and a little bit hot. The first part, 6.5 miles was a little easier. My time was approximately 1h 10 min, but the second part was very difficult. But I was thinking about the patients who have gone through so much treatment and this gave me more strength to finish.
New Approaches to treating Waldenstrom's Macroglobulinemia
At the 2019 Lymphoma & Myeloma Congress, Steven Treon, MD, PhD, FACP, FRCP, Harvard University, Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, Massachusetts, provided an update on the latest research in the treatment of Waldenström Macroglobulinemia.
Dr. Edward Laane - Running for WM!
Dr. Edward Laane is running in the Osaka Yodo River Citizens Marathon to raise money for Waldenstrom's research!
IMW-17 Young Investigator Awards
Congratulations to the following Bing Center researchers for their Young Investigator Awards at the 17th International Workshop on Multiple Myeloma!
IMW-17 Bing Center Poster Presentations
The 17th International Workshop for Multiple Myeloma was held September 12-15, 2019 at the Hynes Convention Center, Boston, MA, USA. The following are the posters presented by the Bing Center for Waldenstrom's Macroglobulinemia.
17th International Workshop on Multiple Myeloma
The International Myeloma Society's 17th International Myeloma Workshop had record-breaking attendance with more than 3,100 attendees from 61 countries for a successful four days of inspiring education, late-breaking research and spirited discussions with old friends and new.
Dr. Jorge Castillo discusses venetoclax at IMW-17 meeting
In this video, Dr. Jorge Castillo, clinical director of the Bing Center for WM, discusses the results of a multicenter, phase II study of venetoclax in patients with previously treated WM. This video was created by OncLive during the 17th International Myeloma Workshop in Boston, MA, Sept 12-15, 2019.
Dr. Castillo's Presentation at the 2019 IWMF Ed Forum
Dr. Jorge Castillo's presentation given at the 2019 Ed Forum, June 9, 2019. The Revolution in WM Treatment: What’s on the Horizon
2019 IWMF Ed Forum - Ask the Doctors
For those of you who provided questions for the Ask the Doctors session at the IWMF Ed Forum, June 9, 2019, you can now view the entire session online.
2019 IWMF Educational Forum
2019 IWMF Educational ForumThe DoubleTree by Hilton Philadelphia Center City – Philadelphia, PAJune 7-9, 2019 The IWMF's annual Educational Forum presents a unique opportunity for patients and caregivers to learn about our disease from world-renowned specialists in Waldenstrom’s macroglobulinemia (WM) who are involved in many areas of clinical practice and research. Held in a different part of the United States every year, the “Ed Forum” offers something for everyone, no matter what your experience or level of knowledge.
The clinical trials listed below have been completed and are closed to enrollment:
Rituximab plus Fludarabine for patients with WM
Phase-2: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Phase II Study of VELCADE (PS-341) in WM
Phase II Study of Thalidomide and Rituximab for patients with WM
Phase II Study of Simvastatin in WM
Phase II Study of Perifosine in Patients with Relapsed/Refractory WM
Phase II Study of Imatinib Mesylate (Gleevec) in Relapsed or Refractory WM
Phase II Study of Combination Therapy with bortezomib and rituximab in patients with relapsed/refractory Waldenstrom’s macroglobulinemia.
Phase II Study of CC-5013 (Lenalidomide , Revlimid(tm)) and rituximab in Waldenstrom's macroglobulinemia
Phase II Clinical Trial of Sildenafil Citrate in WM
Phase II Clinical Trial of RAD001 in relapsed/refractory lymphoma
Phase II Clinical Trial of combination therapy with bortezomib, dexamethasone, and rituximab in patients with WM
Extended Rituximab for patients with WM
Campath-1H for patients with relapsed and refractory WM
An Open Label, Multicenter Phase-2 Study of Single-Agent Enzastaurin HCl in Previously Treaed Waldenstrom's Macroglobulinemia or Multiple Myeloma